Cure JM Research Consortium Receives Prestigious Chan Zuckerberg Grant

Photo of Mark Zuckerberg and Priscilla

The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.

Principal investigators for the grant include Jessica Turnier, M.D., at the University of Michigan, Jessica Neely, M.D., at the University of California, San Francisco; and Andrew Heaton, Ph.D., the Chief Scientific Officer at Cure JM. Other collaborators on the grant include Jeff Dvergsten, M.D. from Duke University, and Lauren Pachman, M.D. from Lurie Children’s Hospital. UCSF, Duke University, and Lurie Children’s Hospital serve as Cure JM Centers of Excellence.

This milestone achievement recognizes Cure JM’s 20-year commitment as a patient advocacy and juvenile myositis research leader. The grant was obtained during an open international competition that included some of science’s most notable researchers. The project was one of five globally awarded projects in the “single cell isolation” category, which focuses on better understanding the cause of rare diseases at the cellular level.  

“The focus of this grant is understanding the role that cell types play in skin, muscle, and blood inflammation to identify new markers and better treatments for JM patients during all phases of the disease,” says Michigan’s Dr. Turnier, who serves as the principal coordinating investigator. “Once we better understand what happens at the cellular level, we may be able to target therapies to those very cells.” 

“Cure JM’s role will be to foster collaboration across our Centers of Excellence and Clinical Care Network,” Dr. Heaton adds. “The evaluators were impressed with the breadth of our organization and the importance of engaging a significant number of JM families from diverse backgrounds in this project. We’re thrilled with Chan Zuckerberg’s confidence in Cure JM.”

The Chan Zuckerberg Initiative was created by Facebook founder Mark Zuckerberg and Priscilla Chan to help solve some of society’s most daunting challenges, including the goal of curing, preventing, and managing all diseases by the end of the century through the combined power of philanthropy, technology, and world-class collaboration. 

Sydney’s Story

Spring break should be about fun and relaxation. Sandi and her husband Zack expected their trip to Mexico would be the same. Of course, taking

Affordable and Accessible Treatments for JM

Affordable and Accessible Treatments for JM

Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.

The FDA’s Ruling on Vamorolone in DMD

You may have heard about yesterday’s FDA ruling, which approved vamorolone as an alternative steroid for use in Duchenne muscular dystrophy.

Vamorolone is a new steroid alternative with fewer side effects than prednisone. The drug aims to preserve the beneficial anti-inflammatory and muscle-strengthening characteristics of corticosteroids, while decreasing some of the unwelcome side effects, including bone fragility, delayed growth, and behavior changes.

As we learned in yesterday’s announcement, vamorolone was found to be both safe and effective as a therapy for Duchenne muscular dystrophy in its newly approved indication.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.